INS and type 2 diabetes mellitus: GPR40 is a pharmacological target to increase insulin secretion in type 2 diabetes, and a synthetic ligand TAK-872 has been shown to induce a β-arrestin-biased pathway instead of G protein signals that are typically elicited by native ligands such as palmitate and oleate (85).